Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01611558 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT01611558 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 40 participants.
The verdict
NCT01611558, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
To assess the incidence of drug-related adverse events of Grade 3 or higher and the overall response associated with ipilimumab treatment
Interventions
- BIOLOGICAL Ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2012-08-21 |
| Est. Completion | 2019-07-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01611558
The ClinicalTrials.gov registry entry for NCT01611558 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ipilimumab is the first listed.
NCT01611558 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01611558 about?
NCT01611558 is a clinical study titled "Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer". To assess the incidence of drug-related adverse events of Grade 3 or higher and the overall response associated with ipilimumab treatment
What is the current status of trial NCT01611558?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2012-08-21. Estimated completion is 2019-07-03.
What interventions are being tested in trial NCT01611558?
The interventions under investigation include: Ipilimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01611558?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.